

Lydia Scarf \tilde{A}^2

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2798970/publications.pdf>

Version: 2024-02-01

91
papers

3,376
citations

147801

31
h-index

155660

55
g-index

92
all docs

92
docs citations

92
times ranked

5692
citing authors

#	ARTICLE	IF	CITATIONS
1	Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 148-151.	5.2	15
2	Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia. <i>Seminars in Cancer Biology</i> , 2022, 84, 329-338.	9.6	4
3	Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1566-1579.	1.3	11
4	Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. <i>British Journal of Haematology</i> , 2022, 198, 103-113.	2.5	7
5	Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 2076.	2.4	6
6	Continuous treatment with Ibrutinib in 100 untreated patients with <i>TP</i>53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	14
7	High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL. <i>Blood Advances</i> , 2022, 6, 5494-5504.	5.2	3
8	Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents. <i>Haematologica</i> , 2021, 106, 2334-2344.	3.5	18
9	Infrequent ðœchronic lymphocytic leukemia-specificðœimmunoglobulin stereotypes in aged individuals with or without low-count monoclonal B-cell lymphocytosis. <i>Haematologica</i> , 2021, 106, 1178-1181.	3.5	8
10	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021, 137, 1365-1376.	1.4	72
11	Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography. <i>Leukemia Research</i> , 2021, 100, 106488.	0.8	3
12	Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 729-739.	7.0	5
13	Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1066-1076.	1.3	3
14	Assessing Patientsâ€™ Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece. <i>HemaSphere</i> , 2021, 5, e546.	2.7	0
15	A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib. <i>Leukemia and Lymphoma</i> , 2021, 62, 2018-2021.	1.3	2
16	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3165-3173.	1.4	539
17	MyPal-Child study protocol: an observational prospective clinical feasibility study of the MyPal ePRO-based early palliative care digital system in paediatric oncology patients. <i>BMJ Open</i> , 2021, 11, e045226.	1.9	9
18	3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells. <i>Frontiers in Immunology</i> , 2021, 12, 639572.	4.8	26

#	ARTICLE	IF	CITATIONS
19	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	1.4	30
20	3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 655773.	3.7	3
21	MyPal ADULT study protocol: a randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies. <i>BMJ Open</i> , 2021, 11, e050256.	1.9	8
22	Fostering Palliative Care Through Digital Intervention: A Platform for Adult Patients With Hematologic Malignancies. <i>Frontiers in Digital Health</i> , 2021, 3, 730722.	2.8	4
23	A First-in-human Study of Tenalisib (RP6530), a Dual PI3K $\hat{\gamma}/\hat{\beta}$ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 78-86.	0.4	19
24	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020, 136, 763-766.	1.4	33
25	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
26	T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities. <i>Clinical Cancer Research</i> , 2020, 26, 4958-4969.	7.0	18
27	Frontline treatment with the combination obinutuzumab \pm chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	4.1	12
28	Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis. <i>British Journal of Haematology</i> , 2020, 189, 475-488.	2.5	13
29	High-throughput analysis of the T cell receptor gene repertoire in low-count monoclonal B cell lymphocytosis reveals a distinct profile from chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, e515.	3.5	3
30	EHA evaluation of the ESMO [®] Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	4.5	10
31	Clonal Hematopoiesis Is Associated with Increased Risk for Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia Patients Treated with Chemo(immuno)Therapy. <i>Blood</i> , 2020, 136, 19-20.	1.4	1
32	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	1.4	1
33	Mutations of the <i>XPO1</i> Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. $\hat{\gamma}$ Training/Validation Study. <i>Blood</i> , 2020, 136, 31-32.	1.4	1
34	Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study. <i>Blood</i> , 2020, 136, 21-22.	1.4	4
35	Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. <i>British Journal of Haematology</i> , 2019, 187, e8-e11.	2.5	14
36	Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. <i>Cancer Immunology Research</i> , 2019, 7, 2036-2051.	3.4	39

#	ARTICLE	IF	CITATIONS
37	Chronic Lymphocytic Leukemia: Who, How, and Where?. Hematologic Malignancies, 2019, , 3-17.	0.2	2
38	Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica, 2019, 104, 2053-2060.	3.5	60
39	Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control. Scientific Reports, 2019, 9, 4155.	3.3	4
40	The evolving treatment landscape of chronic lymphocytic leukemia. Current Opinion in Oncology, 2019, 31, 568-573.	2.4	15
41	Relevance of Minimal Residual Disease in the Era of Targeted Agents. Cancer Journal (Sudbury, Mass), 2019, 25, 410-417.	2.0	8
42	Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment. Leukemia, 2019, 33, 1030-1051.	7.2	4
43	Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica, 2019, 104, 360-369.	3.5	42
44	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. Blood, 2019, 134, 170-170.	1.4	33
45	Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations. Haematologica, 2018, 103, 865-873.	3.5	47
46	No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. Haematologica, 2018, 103, e158-e161.	3.5	16
47	A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression. Nature Communications, 2018, 9, 1787.	12.8	22
48	Monoclonal B-cell lymphocytosis: Does the elderly patient need a specialistic approach?. European Journal of Internal Medicine, 2018, 58, 2-6.	2.2	4
49	A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. Oncotarget, 2018, 9, 26019-26031.	1.8	8
50	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. Lancet Haematology, 2017, 4, e137-e146.	4.6	28
51	Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia. Blood, 2017, 129, 1876-1878.	1.4	63
52	Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. Blood, 2017, 129, 3440-3451.	1.4	56
53	Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 15746.	12.8	93
54	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clinical Cancer Research, 2017, 23, 5292-5301.	7.0	27

#	ARTICLE	IF	CITATIONS
55	The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2419-2425.	1.3	9
56	Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e394-e396.	3.5	10
57	Toll-like receptor 9 stimulation can induce β_2 -microglobulin expression and IgM secretion in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2017, 102, 1901-1912.	3.5	18
58	Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 11219-11227.	1.8	21
59	Chronic lymphocytic leukaemia. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 169-182.	4.4	126
60	Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. <i>Haematologica</i> , 2016, 101, 959-967.	3.5	57
61	What does it mean I have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges. <i>Seminars in Oncology</i> , 2016, 43, 201-208.	2.2	18
62	HIF-1 α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. <i>Blood</i> , 2016, 127, 1987-1997.	1.4	52
63	Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. <i>Cell Reports</i> , 2016, 14, 1748-1760.	6.4	90
64	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. <i>Blood</i> , 2016, 128, 4376-4376.	1.4	1
65	Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4367-4367.	1.4	0
66	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. <i>Blood</i> , 2015, 125, 856-859.	1.4	70
67	Prognostic relevance of MYD88 mutations in CLL: the jury is still out. <i>Blood</i> , 2015, 126, 1043-1044.	1.4	32
68	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2015, 100, e501-e504.	3.5	22
69	Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line. <i>PLoS ONE</i> , 2015, 10, e0130195.	2.5	8
70	AEGLE: A big bio-data analytics framework for integrated health-care services. , 2015, , .		4
71	Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. <i>Haematologica</i> , 2015, 100, 1460-1468.	3.5	19
72	Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>British Journal of Haematology</i> , 2015, 168, 654-662.	2.5	90

#	ARTICLE	IF	CITATIONS
73	Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study). <i>Oncologist</i> , 2014, 19, 291-298.	3.7	70
74	Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). <i>British Journal of Haematology</i> , 2014, 164, 834-840.	2.5	54
75	Monoclonal B cell lymphocytosis and <i>in situ</i> lymphoma. <i>Seminars in Cancer Biology</i> , 2014, 24, 3-14.	9.6	37
76	Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. <i>Lancet Haematology</i> , 2014, 1, e74-e84.	4.6	93
77	The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors. <i>British Journal of Haematology</i> , 2014, 166, 621-625.	2.5	17
78	MBL Versus CLL. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 251-265.	2.2	12
79	Reprogramming cell death: BCL2 family inhibition in hematological malignancies. <i>Immunology Letters</i> , 2013, 155, 36-39.	2.5	107
80	Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 2264-2273.	1.4	50
81	<i>In Vitro</i> Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors. <i>Clinical Cancer Research</i> , 2013, 19, 367-379.	7.0	41
82	Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. <i>Blood</i> , 2013, 121, 4521-4528.	1.4	81
83	Targeting B-cell energy in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 3879-3888.	1.4	73
84	Diagnostic work-up for clinical and prognostic assessment of acute leukaemia. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2012, 8, 26-35.	0.4	1
85	General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. <i>Blood</i> , 2011, 118, 6618-6625.	1.4	131
86	A novel Rag2 ^{-/-} /Irf3 ^{-/-} -xenograft model of human CLL. <i>Blood</i> , 2010, 115, 1605-1609.	1.4	58
87	MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. <i>Blood</i> , 2010, 115, 3949-3959.	1.4	101
88	CLL-like monoclonal B-cell lymphocytosis: Are we all bound to have it?. <i>Seminars in Cancer Biology</i> , 2010, 20, 384-390.	9.6	47
89	Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S61-8.	1.5	43
90	Monoclonal B lymphocytosis in the general population. <i>Leukemia and Lymphoma</i> , 2009, 50, 490-492.	1.3	16

#	ARTICLE	IF	CITATIONS
91	Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models. <i>Oncotarget</i> , 0, 7, 41725-41736.	1.8	9